EXPRESSION OF MULTIDRUG RESISTANCE GENES IN PATIENTS WITH NEWLY DIAGNOSED AND REFRACTORY MULTIPLE MYELOMA
(Abstract release date: 05/21/15)
EHA Library. Chernykh Y. 06/12/15; 102775; PB1852
Yulia Chernykh
Contributions
Contributions
Abstract
Abstract: PB1852
Type: Publication Only
Background
The myeloma cells have the phenomenon of multidrug resistance (MDR), which reduces the effects of chemotherapy. The better understanding of the molecular genetic mechanisms of development of MDR may lead to the development of the individual criteria of prediction of response to cytotoxic treatment of patients with multiple myeloma.
Aims
To determine the expression of four genes associated with MDR, such as MDR1, MRP1, LRP, and BCRP in relation to treatment status. We studied the aspirate of bone marrow of patients with multiple myeloma before cytotoxic treatment and in the resistant group of patients.
Methods
The study included 33 patients (16 men and 17 women) with a diagnosis of multiple myeloma stage 3 by Durie-Salmon system. The age of the patients ranged from 50 to 78 years. 14 patients were investigated before the start of cytostatic treatment. In 19 patients the bone marrow studied after treatment alkylating-containing combinations at the time of registration of resistance to the given therapy. The mRNA expression of the genes was determined by semiquantitative RT-PCR (polymerase chain reaction with reverse transcription) in the mononuclear fraction of the bone marrow aspirate.
Results
Generally, the incidence of mRNA expression of the studied genes MDR in a group of untreated patients was high. The MDR 1 mRNA expression was detected in 93% (13/14) of the samples, the mRNA of the gene MRP 1 was detected in 79% (11/14). The BCRP mRNA expression was detected in 100% of the investigated samples. The expression of mRNA of the gene LRP was identified in 71% of the studied cases (10/14). In the group of patients after treatment the expression of mRNA of genes MDR1, MRP 1, BCRP was detected in 100% of cases, and the LRP mRNA levels detected in 16/19 (84%) of the samples. The expression level of mRNA of each of the tested MDR genes in all studied patients was different. The average value of the expression a total of 4 MDR genes in the group of untreated patients was 3.5±0.72 points. In group of pretreated patients value of the expression has increased to 6.3± 0.54points (p=0.004).
Summary
The expression of mRNA of MDR MRP 1, MDR 1, BCRP, LRP was determined in patients with untreated multiple myeloma. The intensity of gene expression increases in resistant patients.
Keyword(s): Multidrug resistance, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
The myeloma cells have the phenomenon of multidrug resistance (MDR), which reduces the effects of chemotherapy. The better understanding of the molecular genetic mechanisms of development of MDR may lead to the development of the individual criteria of prediction of response to cytotoxic treatment of patients with multiple myeloma.
Aims
To determine the expression of four genes associated with MDR, such as MDR1, MRP1, LRP, and BCRP in relation to treatment status. We studied the aspirate of bone marrow of patients with multiple myeloma before cytotoxic treatment and in the resistant group of patients.
Methods
The study included 33 patients (16 men and 17 women) with a diagnosis of multiple myeloma stage 3 by Durie-Salmon system. The age of the patients ranged from 50 to 78 years. 14 patients were investigated before the start of cytostatic treatment. In 19 patients the bone marrow studied after treatment alkylating-containing combinations at the time of registration of resistance to the given therapy. The mRNA expression of the genes was determined by semiquantitative RT-PCR (polymerase chain reaction with reverse transcription) in the mononuclear fraction of the bone marrow aspirate.
Results
Generally, the incidence of mRNA expression of the studied genes MDR in a group of untreated patients was high. The MDR 1 mRNA expression was detected in 93% (13/14) of the samples, the mRNA of the gene MRP 1 was detected in 79% (11/14). The BCRP mRNA expression was detected in 100% of the investigated samples. The expression of mRNA of the gene LRP was identified in 71% of the studied cases (10/14). In the group of patients after treatment the expression of mRNA of genes MDR1, MRP 1, BCRP was detected in 100% of cases, and the LRP mRNA levels detected in 16/19 (84%) of the samples. The expression level of mRNA of each of the tested MDR genes in all studied patients was different. The average value of the expression a total of 4 MDR genes in the group of untreated patients was 3.5±0.72 points. In group of pretreated patients value of the expression has increased to 6.3± 0.54points (p=0.004).
Summary
The expression of mRNA of MDR MRP 1, MDR 1, BCRP, LRP was determined in patients with untreated multiple myeloma. The intensity of gene expression increases in resistant patients.
Keyword(s): Multidrug resistance, Multiple myeloma
Session topic: Publication Only
Abstract: PB1852
Type: Publication Only
Background
The myeloma cells have the phenomenon of multidrug resistance (MDR), which reduces the effects of chemotherapy. The better understanding of the molecular genetic mechanisms of development of MDR may lead to the development of the individual criteria of prediction of response to cytotoxic treatment of patients with multiple myeloma.
Aims
To determine the expression of four genes associated with MDR, such as MDR1, MRP1, LRP, and BCRP in relation to treatment status. We studied the aspirate of bone marrow of patients with multiple myeloma before cytotoxic treatment and in the resistant group of patients.
Methods
The study included 33 patients (16 men and 17 women) with a diagnosis of multiple myeloma stage 3 by Durie-Salmon system. The age of the patients ranged from 50 to 78 years. 14 patients were investigated before the start of cytostatic treatment. In 19 patients the bone marrow studied after treatment alkylating-containing combinations at the time of registration of resistance to the given therapy. The mRNA expression of the genes was determined by semiquantitative RT-PCR (polymerase chain reaction with reverse transcription) in the mononuclear fraction of the bone marrow aspirate.
Results
Generally, the incidence of mRNA expression of the studied genes MDR in a group of untreated patients was high. The MDR 1 mRNA expression was detected in 93% (13/14) of the samples, the mRNA of the gene MRP 1 was detected in 79% (11/14). The BCRP mRNA expression was detected in 100% of the investigated samples. The expression of mRNA of the gene LRP was identified in 71% of the studied cases (10/14). In the group of patients after treatment the expression of mRNA of genes MDR1, MRP 1, BCRP was detected in 100% of cases, and the LRP mRNA levels detected in 16/19 (84%) of the samples. The expression level of mRNA of each of the tested MDR genes in all studied patients was different. The average value of the expression a total of 4 MDR genes in the group of untreated patients was 3.5±0.72 points. In group of pretreated patients value of the expression has increased to 6.3± 0.54points (p=0.004).
Summary
The expression of mRNA of MDR MRP 1, MDR 1, BCRP, LRP was determined in patients with untreated multiple myeloma. The intensity of gene expression increases in resistant patients.
Keyword(s): Multidrug resistance, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
The myeloma cells have the phenomenon of multidrug resistance (MDR), which reduces the effects of chemotherapy. The better understanding of the molecular genetic mechanisms of development of MDR may lead to the development of the individual criteria of prediction of response to cytotoxic treatment of patients with multiple myeloma.
Aims
To determine the expression of four genes associated with MDR, such as MDR1, MRP1, LRP, and BCRP in relation to treatment status. We studied the aspirate of bone marrow of patients with multiple myeloma before cytotoxic treatment and in the resistant group of patients.
Methods
The study included 33 patients (16 men and 17 women) with a diagnosis of multiple myeloma stage 3 by Durie-Salmon system. The age of the patients ranged from 50 to 78 years. 14 patients were investigated before the start of cytostatic treatment. In 19 patients the bone marrow studied after treatment alkylating-containing combinations at the time of registration of resistance to the given therapy. The mRNA expression of the genes was determined by semiquantitative RT-PCR (polymerase chain reaction with reverse transcription) in the mononuclear fraction of the bone marrow aspirate.
Results
Generally, the incidence of mRNA expression of the studied genes MDR in a group of untreated patients was high. The MDR 1 mRNA expression was detected in 93% (13/14) of the samples, the mRNA of the gene MRP 1 was detected in 79% (11/14). The BCRP mRNA expression was detected in 100% of the investigated samples. The expression of mRNA of the gene LRP was identified in 71% of the studied cases (10/14). In the group of patients after treatment the expression of mRNA of genes MDR1, MRP 1, BCRP was detected in 100% of cases, and the LRP mRNA levels detected in 16/19 (84%) of the samples. The expression level of mRNA of each of the tested MDR genes in all studied patients was different. The average value of the expression a total of 4 MDR genes in the group of untreated patients was 3.5±0.72 points. In group of pretreated patients value of the expression has increased to 6.3± 0.54points (p=0.004).
Summary
The expression of mRNA of MDR MRP 1, MDR 1, BCRP, LRP was determined in patients with untreated multiple myeloma. The intensity of gene expression increases in resistant patients.
Keyword(s): Multidrug resistance, Multiple myeloma
Session topic: Publication Only
{{ help_message }}
{{filter}}